Patents Assigned to Cedilla Therapeutics, Inc.
  • CDK2 inhibitors and methods of using the same
    Patent number: 12065445
    Abstract: The present disclosure provides compounds according to Formula I or a pharmaceutically acceptable salt thereof: wherein each variable is as defined and described herein, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
    Type: Grant
    Filed: January 28, 2022
    Date of Patent: August 20, 2024
    Assignee: Cedilla Therapeutics, Inc.
    Inventors: Louise Clare Kirman, Carl Eric Schwartz, Wojtek Michowski, Dale A. Porter, Jr., Justin Ripper, John Feutrill, John Paul Sherrill, Thomas P. Blaisdell
  • CDK2 inhibitors and methods of using the same
    Patent number: 12053459
    Abstract: The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: August 6, 2024
    Assignee: Cedilla Therapeutics, Inc.
    Inventors: Louise Clare Kirman, Carl Eric Schwartz, Wojtek Michowski, Dale A. Porter, Jr., Justin Ripper, John Feutrill
  • CDK2 INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20240174680
    Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.
    Type: Application
    Filed: January 28, 2022
    Publication date: May 30, 2024
    Applicant: Cedilla Therapeutics, Inc.
    Inventors: Louise Clare KIRMAN, Carl Eric SCHWARTZ, Wojtek MICHOWSKI, Dale A. PORTER, JR., Justin RIPPER, John FEUTRILL, John Paul SHERRILL, Thomas P. BLAISDELL